首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.
【24h】

Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.

机译:在非酒精性脂肪性肝炎的高脂喂养小鼠肥胖模型中,糖尿病是肝纤维化的进展因素。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND & AIMS: While type 2 diabetes is an independent risk factor for worsening of human non-alcoholic steatohepatitis (NASH) in clinical studies, it has not been systematically reported in any model whether diabetes exacerbates NASH. The study aim was to determine if diabetes causes NASH progression in a mouse model of diet induced obesity. METHODS: C57BL/6 mice were fed a high fat diet (HFD: 45% kcal fat) or standard chow (CHOW: 12% kcal fat) for 20 weeks and some animals (HFD+DM or CHOW+DM) were also rendered diabetic by low dose streptozotocin for the final 5 weeks, to model type 2 diabetes. Serum assays included circulating insulin, triglyceride, ALT and AST, glucose, and ultrasensitive CRP and results of insulin tolerance tests. Intrahepatic lipid, triglyceride, macrophage infiltration, and fibrosis were determined. Fibrosis markers collagen-I, collagen-III, CTGF, TIMP-1, and FAP were assessed by qPCR and CTGF and collagen-I by immunostaining. RESULTS: HFD mice were obese, insulin resistant and hyperinsulinaemic, with NASH features of elevated intrahepatic lipid and macrophages, but without fibrosis. In contrast, the HFD+DM mice exhibited fibrosis in addition to these NASH features. By ANOVA, Sirius red staining at perisinusoidal, portal tract and central vein sites, collagen-I, collagen-III, FAP, and TIMP-1 transcripts and collagen-I and CTGF protein were each significantly increased in HFD+DM, compared with CHOW alone. In a further experiment, insulin treatment protected against fibrosis and CRP increases in HFD+DM, showing that diabetes, not streptozotocin, causes the fibrosis. CONCLUSIONS: This novel model indicates that diet-induced NASH fibrosis is exacerbated by diabetes and attenuated by insulin therapy.
机译:背景与目的:尽管在临床研究中2型糖尿病是导致人类非酒精性脂肪性肝炎(NASH)恶化的独立危险因素,但尚未在任何模型中系统地报道糖尿病是否会加剧NASH。该研究的目的是确定在饮食诱发的肥胖小鼠模型中,糖尿病是否会引起NASH进展。方法:给C57BL / 6小鼠喂高脂饮食(HFD:45%大卡脂肪)或标准食物(CHOW:12%大卡脂肪),持续20周,还对某些动物(HFD + DM或CHOW + DM)进行了糖尿病治疗在最后5周内使用低剂量的链脲佐菌素治疗2型糖尿病。血清测定包括循环胰岛素,甘油三酸酯,ALT和AST,葡萄糖和超敏CRP以及胰岛素耐受性测试的结果。测定肝内脂质,甘油三酸酯,巨噬细胞浸润和纤维化。通过qPCR评估纤维化标记物胶原蛋白I,胶原蛋白III,CTGF,TIMP-1和FAP,并通过免疫染色评估CTGF和胶原蛋白I。结果:HFD小鼠肥胖,胰岛素抵抗和高胰岛素血症,具有NASH特征,肝内脂质和巨噬细胞升高,但无纤维化。相反,除了这些NASH功能外,HFD + DM小鼠还表现出纤维化。通过方差分析,与CHOW相比,HFD + DM患者的窦窦,门脉和中枢静脉部位的天狼星红染色,胶原蛋白I,胶原蛋白III,FAP和TIMP-1转录本以及胶原蛋白I和CTGF蛋白均显着增加单独。在进一步的实验中,胰岛素治疗可防止纤维化,而HFD + DM中的CRP升高,表明糖尿病而非链脲佐菌素可引起纤维化。结论:这种新型模型表明,饮食引起的NASH纤维化会因糖尿病而加剧,并因胰岛素治疗而减弱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号